Hamburg (ots) - Regina Biliz (29) ist ab 1. Juni 2018 Grafikdesignerin bei news aktuell. Die studierte ...
Dosing for RVX-208 Phase 1a Clinical Study Completed
Calgary, Canada (ots/PRNewswire) - - Phase 1a Study Objectives Were Met
- TSX Exchange Symbol: RVX
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead drug candidate, RVX-208, which addresses the dyslipidemia market. "Initial results from the emerging data are very good," declared Donald J. McCaffrey, President & CEO of Resverlogix. "As reported earlier this year the most remarkable results from this study continue to be the outstanding pharmacokinetics (drugability) of RVX-208. With these successful results in hand we are now planning for our Phase 1b/2a trial which, pending discussions and approval from the FDA, we expect to start later this year."
The primary objectives of the Phase 1a trial were to examine the safety, tolerability and pharmacokinetics of RVX-208. This study successfully met those objectives. In addition to the completed Phase 1a human clinical trial, RVX-208 has been the subject of 126 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and pharmacology studies. The Company has selected the dosages to be used in the 28-day Phase 1b/2a study.
"We are very pleased with these promising results which indicate that RVX-208 is a safe and well tolerated drug," stated Dr. Jan Johansson, MD, PhD, Senior Vice President Medical Affairs of Resverlogix. "We are in the process of finalizing the tables, figures and legends for this past study." A review of the pharmacokinetic data was recently presented at the Arteriosclerosis, Thrombosis and Vascular Biology conference in Atlanta, GA.
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease which can lead to heart attacks), cerebrovascular disease (stroke), and hypertension (high blood pressure). The underlying cause of most CVD is a gradual clogging of the arteries (atherosclerosis) that supply blood to the heart, brain and other vital organs.
The American Heart Association estimates that almost 80 million American Adults have one or more types of cardiovascular disease. CVD remains the number one killer of developed nations. Nearly 2400 Americans die each day from cardiovascular disease - that is 1 person will die every 36 seconds.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax: +1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: +1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com; Website: http://www.resverlogix.com
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com